The impact of delayed hepatitis C viral load suppression on patient risk: Historical evidence from the veterans administration

Forum for Health Economics and Policy

Volumn 19, Issue 2, 2016, Pages 333-351

  Matsuda, Tara ^a   McCombs, Jeffrey S ^a   Tonnu Mihara, Ivy ^b   McGinnis, Justin ^a   Fox, D Steven ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Delayed viral response; Hepatitis C; Triage of treatments; Watchful waiting

Indexed keywords

EID: 85010061519     PISSN: None     EISSN: 15589544     Source Type: Journal    
DOI: 10.1515/fhep-2015-0041     Document Type: Article

References (38)

1. American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. When and in whom to initiate HCV therapy. Available at: http://hcvguidelines.org/ full-report/when-and-whom-initiate-hcv-therapy. Accessed August 14, 2014.
2. Backus, L. I., S. Gavrilov, T. P. Loomis, J. P. Halloran, B. R. Phillips, P. S. Belperio and L. A. Mole (2009) "Clinical Case Registries: Simultaneous Local and National Disease Registries for Population Quality Management," Journal of the American Medical Informatics Association, 16(6):775-783.
3. Backus, L. I., D. B. Boothroyd, B. R. Phillips, P. Belperio, J. Halloran and L. A. Mole (2011) "A Sustained Virologic Response Reduces Risk of All-Cause Mortality in Patients with Hepatitis C," Clinical Gastroenterology and Hepatology, 9:509-516.e1.
4. Bonnard, P., A. Elsharkawy, K. Zalata, E. Delarocque-Astagneau, L. Biard, L. Le Fouler, A. B. Hassan, M. Abdel-Hamid, M. El-Daly, M. E. Gamal, M. El Kassas, P. Bedossa, F. Carrat, A. Fontanet and G. Esmat (2015) "Comparison of Liver Biopsy and Noninvasive Techniques for Liver Fibrosis Assessment in Patients Infected with HCV-genotype 4 in Egypt," Journal of Viral Hepatitis, 22:245-253.
5. Butt, A. A., X. Wang and C. G. Moore (2009) "Effect of Hepatitis C Virus and Its Treatment on Survival," Hepatology, 50(8):387-392.
6. Butt, A. A., P. Yan, V. Lo Re, 3rd, D. Rimland, M. B. Goetz, D. Leaf, M. S. Freiberg, M. B. Klein, A. C. Justice and K. E. Sherman; ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans) Study Team (2015) "Liver Fibrosis Progression in Hepatitis C Virus Infection After Seroconversion," Journal of the American Medical Association Internal Medicine, 172(2):178-185.
7. Center for Quality Management in Public Health (2010) "The State of Care for Veterans with Chronic Hepatitis C." US Department of Veteran Affairs, Public Health Strategic Health Care Group, Center for Quality Management in Public Health, Palo Alto, CA.
8. Chen, S. L. and T. R. Morgan (2006) "The Natural History of Hepatitis C Virus (HCV) Infection. International Journal of Medical Sciences, 3(2):47-52.
9. Chen, J., J. Florian, W. Carter, R. D. Fleischer, T. S. Hammerstrom, P. R. Jadhav, W. Zeng, J. Murray and D. Birnkrant (2013) Earlier Sustained Virologic Response End Points for Regulatory Approval and dose Selection of Hepatitis C Therapies," Gastroenterology, 144(7):1450-1455.e2.
10. Crosse, K., O. G. Umeadi, F. A. Anania, J. Laurin, J. Papadimitriou, C. Drachenberg and C. D. Howell (2004) "Racial Differences in Liver Inflammation and Fibrosis Related to Chronic Hepatitis C," Clinical Gastroenterology and Hepatology, 2(6):463-468.
11. Davis, G. L., J. E. Albright, S. F. Cook and D. M. Rosenberg (2003) "Projecting Future Complications of Chronic Hepatitis C in the United States," Liver Transplantation, 9(4):331-338.
12. Denniston, M. M., R. B. Jiles, J. Drobeniuc, R. M. Klevens, J. W. Ward, G. M. McQuillan and S. D. Holmberg (2014) "Chronic Hepatitix C Virus Infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010," Annals of Internal Medicine, 160(5):293-300.
13. Ditah, I., F. Ditah, P. Devaki, O. Ewelukwa, C. Ditah, B. Njei, H. N. Luma and M. Charlton (2014) "The Changing Epidemiology of Hepatitis C Virus Infection in the United States: National Health and Nutrition Examination Survey 2001 to 2010," Journal of Hepatology, 60(4):691-698.
14. El-Serag, H. B. and A. C. Mason (2000) "Risk Factors for the Rising Rates of Primary Liver Cancer in the United Stats," Archives of Internal Medicine, 160(21):3227-3230.
15. Fried, Michael W., M. L. Shiffman, K. R. Reddy, C. Smith, G. Marinos, F. L. Goncales Jr, D. Haussinger, M. Diago, G. Carosi, D. Dhumeaux, A. Craxi, A. Lin, J. Hoffman and J. Yu (2002) "Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection," New England Journal of Medicine, 347(13):975-982.
16. Ghany, M. G., A. S. Lok, J. E. Everhart, G. T. Everson, W. M. Lee, T. M. Curto, E. C. Wright, A. M. Stoddard, R. K. Sterling, A. M. Di Bisceglie, H. L. Bonkovsky, C. Morishima, T. R. Morgan and J. L. Dienstag; HALT-C Trial Group (2010) "Predicting Clinical and Histologic Outcomes Based on Standard Laboratory Tests in Advanced Chronic Hepatitis C," Gastroenterology, 138:136-146.
17. Holmberg, S. D., M. Lu, L. B. Rupp, L. E. Lamerato, A. C. Moorman, V. Vijayadeva, J. A. Boscarino, E. M. Henkle and S. C. Gordon; Chronic Hepatitis Cohort Study (CHeCS) Investigators (2013) "Noninvasive Serum Fibrosis Markers for Screening and Staging Chronic Hepatitis C Virus Patients in a Large US Cohort," Clinical Infectious Diseases, 57:240-246.
18. Kallwitz, E. R., J. Layden-Almer, M. Dhamija, J. Berkes, G. Guzman, R. Lepe, S. J. Cotler and T. J. Layden (2010) "Ethnicity and Body Mass Index are Associated with Hepatitis C Presentation and Progression," Clinical Gastroenterology and Hepatology, 8(1):72-78.
19. Kanwal, F., J. R. Kramer, J. Ilyas, Z. Duan and H. B. El-Serag (2014) "HCV Genotype 3 is Associated with an Increased Risk of Cirrhosis and Hepatocellular Cancer in a National Sample of U.S. Veterans with HCV," Hepatology, 60:98-105.
20. Klevens, R. M., D. J. Hu, R. Jiles and S. D. Holmberg (2012) "Evolving Epidemiology of Hepatitis C Virus in the United States," Clinical Infectious Diseases, 55(Suppl 1):S3-S9.
21. Kobayashi, M., E. Tanaka, T. Sodeyama, A. Urushihara, A. Matsumoto and K. Kiyosawa (1996) "The Natural Course of Chronic Hepatitis C: A Comparison Between Patients with Genotypes 1 and 2 Hepatitis C Viruses," Hepatology, 23:695-699.
22. Larsen, C., V. Bousquet, E. Delarocque-Astagneau, C. Pioche, F. Roudot-Thoraval; HCV Surveillance Steering Committee; HCV Surveillance Group and J. C. Desenclos (2010) "Hepatitis C Virus Genotype 3 and the Risk of Severe Liver Disease in a Large Population of Drug Users in France," Journal of Medical Virology, 82(10):1647-1654.
23. Lavanchy, D. (2009) "The Global Burden of Hepatitis C," Liver International, 29(Suppl 1):74-81.
24. Lee, M. H., H. I. Yang, S. N. Lu, C. L. Jen, S. L. You, L. Y. Wang, C. H. Wang, W. J. Chen and C. J. Chen; R.E.V.E.A.L.-HCV Study Group (2012) "Chronic Hepatitic C Virus Infection Increases Mortality from Hepatic and Extrahepatic Diseases: A Community-Based Long-Term Prosepctive Study," The Journal of Infectious Diseases, 206:469-477.
25. Loftus, P. (2013) "Patient Dilemma: Treat Hepatitic C Now or Hold Out?" Wall Street Journal. Available at: http://www.wsj.com/articles/SB1000142412788732329370457833071244235 3712. Accessed May 30, 2015.
26. McCombs, J., T. Matsuda, I. Tonnu-Mihara, S. Saab, P. Hines, G. L'italien, T. Juday and Y. Yuan (2014) "The Risk of Long-Term Morbidity and Mortality in Patients with Chronic Hepatitis C: Results from an Analysis of Data from a Department of Veterans Affairs Clinical Registry," Journal of the American Medical Association Internal Medicine, 174:204-212.
27. Ng, V. and S. Saab (2011) "Effects of a Sustained Virologic Response on Outcomes of Patients with Chronic Hepatitis C," Clinical Gastroenterology and Hepatology, 9(11):923-930.
28. Rein, D. B., J. S. Wittenborn, C. M. Weinbaum, M. Sabin, B. D. Smith and S. B. Lesesne (2011) "Forecasting the Morbidity and Mortality Associated with Prevalent Cases of Pre-Cirrhotic Chronic Hepatitis C in the United States," Digestive and Liver Disease, 43(1):66-72.
29. Sanchez-Conde, M., M. L. Montes-Ramirez, P. Miralles, J. M. Alvarez, J. M. Bellon, M. Ramirez, J. R. Arribas, I. Gutierrez, J. C. Lopez, J. Cosin, E. Alvarez, J. Gonzalez and J. Berenguer (2010) "Comparison of Transient Elastography and Liver Biopsy for the Assessment of Liver Fibrosis in HIV/Hepatitis C Virus-Coinfected Patients and Correlation with Noninvasive Serum Markers," Journal of Viral Hepatitis, 17:280-286.
30. Seeff, L. B. (2009) "The History of the 'Natural History' of Hepatitis C (1968-2009)," Liver International, 29(Suppl 1):89-99.
31. Sterling, R. K., R. T. Stravitz, V. A. Luketic, A. J. Sanyal, M. J. Contos, A. S. Mills and M. L. Shiffman (2004) "A Comparison of the Spectrum of Chronic Hepatitis C Virus Between Caucasians and African Americans," Clinical Gastroenterology and Hepatology, 2(6):469-473.
32. Sterling, R. K., E. Lissen, N. Clumeck, R. Sola, M. C. Correa, J. Montaner, M. S. Sulkowski, F. J. Torriani, D. T. Dieterich, D. L. Thomas, D. Messinger and M. Nelson; APRICOT Clinical Investigators (2006) "Development of a Simple Noninvasive Index to Predict Significant Fibrosis in Patients with HIV/HCV Coinfection," Hepatology, 43:1317-1325.
33. Vallet-Pichard, A., V. Mallet, B. Nalpas, V. Verkarre, A. Nalpas, V. Dhalluin-Venier, H. Fontaine and S. Pol (2007) "FIB-4: An Inexpensive and Accurate Marker of Fibrosis in HCV Infection. Comparison with Liver Biopsy and Fibrotest," Hepatology, 46(1):32-36.
34. van der Meer, A. J., B. J. Veldt, J. J. Feld, H. Wedemeyer, J. F. Dufour, F. Lammert, A. Duarte-Rojo, E. Heathcote, M. P. Manns, L. Kuske, S. Zeuzem, W. P. Hofmann, R. J. de Knegt, B. E. Hansen and H. L. Janssen (2012) "Association Between Sustained Virological Response and All- Cause Mortality Among Patients with Chronic Hepatitis C and Advanced Hepatic Fibrosis," Journal of the American Medical Association, 308(24):2584-2593.
35. van der Meer, A. J., B. E. Hansen, G. Fattovich, J. J. Feld, H. Wedemeyer, J. F. Dufour, F. Lammert, A. Duarte-Rojo, M. P. Manns, D. Ieluzzi, S. Zeuzem, W. P. Hofmann, R. J. de Knegt, B. J. Veldt and H. L. Janssen (2015) "Reliable Prediction of Clinical Outcome in Patients with Chronic HCV Infection and Compensated Advanced Hepatic Fibrosis: A Validated Model Using Objective and Readily Available Clinical Parameters," Gut, 64(2):322-331.
36. Vergniol, J., J. Foucher, E. Terrebonne, P. H. Bernard, B. le Bail, W. Merrouche, P. Couzigou and V. de Ledinghen (2011) "Noninvasive Tests for Fibrosis and Liver Stiffness Predict 5-year Outcomes of Patients with Chronic Hepatitis C," Gastroenterology, 140:1970-1979.e3.
37. Xu, F., J. Xing, A. C. Moorman, S. C. Gordon, L. B. Rupp, M. Lu, P. R. Spradling, E. H. Teshale, J. A. Boscarino, V. Vijayadeva, M. A. Schmidt (2014) FIB-4 Score and Gender Predict the Incidence of Hepatocellular Carcinoma (HCC) among Patients with Chronic Hepatitis C Virus (HCV) Infection: Chronic Hepatitis Cohort Study (CHeCS) 65th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA.
38. Zhou, S., N. A. Terrault, L. Ferrell, J. A. Hahn, J. Y. Lau, P. Simmonds, J. P. Roberts, J. R. Lake, N. L. Ascher and T. L. Wright (1996) "Severity of Liver Disease in Liver Transplantation Recipients with Hepatitis C Virus Infection: Relationship to Genotype and Level of Viremia," Hepatology, 24(5):1041-1046.